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ABSTRACT
Background: According to Globocan, Mongolia has
the highest worldwide hepatocellular carcinoma
(HCC) incidence (78.1/100 000, 3.5× higher than
China).
Aims and methods: We conducted an anonymous
survey of physicians from major provinces who
attended an educational liver symposium, analysing
their demography, practice, knowledge, perceptions
and proposed solutions. Multivariate logistic regression
was used to estimate OR relating demography and
practice factors with higher provider knowledge and
improvement.
Results: Of the 121 attendees, 44–95 (36–79%)
responded to each question. Most were female (87%),
young (79% age <50), subspecialists (81%),
university-affiliated (74%), and practised in urban
areas (61%). The mean pretest and post-test scores
per physician were 60.4±20.4 and 65.6±21.3, with no
observed significant predictors for baseline knowledge
or improvement. Most (>80%) noted that <50% of
patients who need hepatitis or HCC screening receive
it. The main perceived barriers to screening were
inability to pay for tests, lack of guidelines and poor
patient awareness. Hepatitis treatment rates were low;
83% treated hepatitis C virus in <10 patients in the
past year, and 86% treated hepatitis B virus in <10
patients/month. Treatment barriers were multifactorial,
with cost as a principal barrier. Proposed solutions
were universal screening policies (46%), removal of
financial barriers (28%) and provider education
(20%).
Conclusions: Physicians from major regions of
Mongolia noted low screening for viral hepatitis, even
lower treatment rates, financial barriers and the need
for increased educational efforts. We advocate broad-
based medical education tailored to local needs and
based on needs assessment and outcome
measurements.
Summary box
What is already known about this subject?
▸ Mongolia has the highest hepatocellular carcin-
oma (HCC) incidence in the world (78.1/100,000,
3.5× higher than China). As a result, the
Mongolia government has launched The National
Viral Hepatitis Program, which is a comprehen-
sive program that involves all aspects from pre-
vention to care and disease control to meet a
reduction goal for morbidity and mortality due to
HBV, HDV and HCV (the three primary causes of
HCC in Mongolia). Consequently, access to anti-
viral therapies is now improving in Mongolia.
What does this study add?
▸ For the first time, we formally and anonymously
evaluated physician’s knowledge of liver disease,
readiness to treat with the newer therapies, their
perceptions on barriers to screening, diagnosis
and treatment, and proposed solutions in a sample
of physicians from both urban and rural practices
and from all major provinces of Mongolia. This
work outlines a practical process and simple pro-
vider survey methodology and format that can be
applied to other developing countries for needs
assessment that can also be applicable to a variety
of topics, as formal needs assessment is important
to obtain data to guide future educational and
research efforts and to assist with resource alloca-
tion to improve access to care as well as to expand
the current levels of care.
How might this impact on clinical practice?
▸ The survey showed that, in addition to removal of
financial barriers for screening, diagnosis and treat-
ment in low and middle income countries, provider
knowledge and comfort with the management of
diseases are also very important. Understanding
provider educational needs and targeting programs
according to specific knowledge and access gaps
identified will set the foundation for expanding care
efficiently and effectively.
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INTRODUCTION
Currently, on a global scale, viral hepatitis is a signiﬁcant
cause of death.1 Mongolia has the highest worldwide
hepatocellular carcinoma (HCC) incidence in the world
(78.1/100 000), according to Globocan.2 This incidence
is three and a half times higher than in China, and six
times higher than the global average. In a small low to
middle income country of 2 992 908 people with a gross
domestic product (GDP) of $11 900 per capita, liver
disease causes substantial morbidity and mortality.3 The
number one cause of cancer-related death was HCC,
responsible for 44% of male and 42% of female cancer
deaths.4 5 In addition, data from the National Cancer
Registry of Mongolia found that the leading cause of
cancer was also HCC in both genders (41% of male
cancers; 33% of female cancers).4 Furthermore, the inci-
dence of HCC has increased from 10 to 60 per 100 000
from the 1960s to 2010.5 In 2014, the liver cancer mor-
bidity and mortality were 64.4 and 47.4 per 100 000
persons according to the Center for Health
Development Health Indicators report.6 In a retrospect-
ive study conducted with 195 consecutive patients with
HCC from four hospitals in Ulaanbaatar in 2012, the
primary aetiologies of HCC were found to be hepatitis C
virus (HCV) (45.6%), hepatitis B virus (HBV) (34.4%),
HBV and HCV dual infection (14.4%) and alcoholic
liver disease (5.6%).7
Mongolia introduced HBV vaccination into routine
immunisation schedules for newborns and children
under 1 year of age in 1991, which substantially
decreased the incidence of HBV infection.8 In addition,
an randomised controlled trial (RCT) shows that the
drug tenofovir disoproxil fumarate (TDF) can safely
prevent vertical transmission of HBV, and could further
improve this decrease in HBV infection.9 The WHO sup-
ported a series of national serological surveys and found
that Mongolia reached its regional goal, with 82% of
children fully vaccinated as of 2010.7 The hepatitis B
surface antigen (HBsAg) carrier rate was 0.53 among
5894 children aged 4–6 years in 2009–2010.7 However,
the prevalence of HBV is still high among adults. A
review of studies from 2000 to 2011 found an HBV sero-
prevalence of 11.8% in the unvaccinated population.5
Approximately 13.6% of those who are HBsAg-positive
also have coinfection with the hepatitis D virus (HDV),
which speeds progression of liver disease.10–12
The prevalence of HCV, the other leading cause of
HCC, was also found to be high at 15%.5 Although HCV
can now be cured with new direct-acting antiviral (DAA)
therapies, the morbidity and mortality are still high, due
to delayed diagnoses and poor access to newer medica-
tions. The seroprevalence of dual infection with HBV
and HCV was found to range from 5.3% to 22.9% in the
published literature.5 13–18
Access to antiviral therapies is now improving in
Mongolia. The HCV DAAs, sofosbuvir and a ﬁxed-dose
combination of ledipasvir and sofosbuvir (LDV/SOF),
have been registered and are available at lower costs.19 20
In addition, TDF for the treatment of HBV is also more
affordable based on a new tiered pricing strategy.19 20 In
response, the Mongolian Ministry of Health and Sports
(MOHS) has recently developed hepatitis C diagnosis
and treatment guidelines for medical practitioners, and
is currently working on updating hepatitis B guide-
lines.19 20 However, there are no current data on phys-
ician awareness and management of this important
disease, and whether these physicians possess knowledge
on the optimal use of these newer therapies.
Our goal was to evaluate Mongolian physicians’ knowl-
edge of liver disease, their comfort level in the manage-
ment of liver disease, their access and perceived barriers
to screening, diagnosis and treatment and their pro-
posed solutions.
METHODS
Study design
We conducted an anonymous survey of physicians from
all major provinces of Mongolia who attended a 2-day
continuing medical education liver symposium in
Ulaanbaatar, Mongolia in 21–22 September 2015.
During the symposium, international experts in liver
disease led interactive sessions on hepatitis viruses (HBV,
HCV, HDV), end-stage liver disease (ESLD) and HCC.
Local hepatologists led and moderated the case study
discussions after each module and administered the
survey in the Mongolian language.
Surveys were administered at regular intervals through-
out the sessions to evaluate the following:
1. Demographic and medical practice;
2. Knowledge (pretest and post-test to assess baseline
knowledge and improvement, and case study ques-
tions for each module) and perceived familiarity on
liver disease management;
3. Perceived barriers to screening, diagnosis and
treatment;
4. Proposed solutions.
We administered paper surveys for the demographic
and practice questions, and the audience response
system (ARS) was used for the remaining surveys to
display and record and tabulate answers. We were able
to match the demographics of the participants with
their responses to the ARS by recording the ARS hand-
held device number on the paper surveys. All written
materials including paper surveys, slides of survey ques-
tions, lecture slides and course syllabus were in the
Mongolian language. Lecture slides were presented both
in English and Mongolian. Mongolian hepatologists
reviewed the medical integrity of the translated course
material and survey to ensure proper wording and trans-
lation. Survey questions were read by Mongolian hepa-
tology experts in Mongolian to participants. All lectures
were conducted in English with parallel live translation
into Mongolian by Mongolian physicians serving as
translators.
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Statistical analysis
Summary statistics were performed on all surveys using
STATA (StataCorp LP, College Station, Texas, USA).
Scores for knowledge-based questions were calculated as
a percentage of correct answers for all questions in
those who answered ≥1 question. Multivariate logistic
regression was used to estimate OR relating factors such
as physician demography, practice setting, perceived
comfort with managing liver disease with higher pro-
vider knowledge (>50% score) and improvement. We
also evaluated predictors of perceived comfort with
managing liver disease. This study received an
Institutional Review Board exemption from the Panel
on Human Subjects at Stanford University, Stanford,
California, USA.
RESULTS
A total of 121 physicians attended the symposium repre-
senting all major regions of Mongolia. Most were female
(86.9%), age ≤50 (78.5%), subspecialists (81.1%), uni-
versity afﬁliated (74.0%), and practised in urban versus
rural areas (61.2% vs 38.8%) (table 1).
A majority of physicians (78.1%) manage more
than 10 patients per week with liver disease, with 40.0%
of physicians seeing more than a quarter with HCV, and
33.7% seeing more than a quarter with HBV (table 2).
Knowledge and perceived familiarity with liver disease
management
Of the 121 attendees, 44–89 (36.4–73.6%) responded to
each question of the 12 pretest and post-test questions
and 30 case study questions. The majority (50–75%) of
physicians answered 58.3% of the pretest questions,
91.7% of the post-test questions and 73.3% of the case
study questions. The mean pretest and post-test scores
per physician were 60.4±20.4 and 65.6±21.3, with no
observed signiﬁcant predictors for high baseline knowl-
edge or improvement. Of the case questions, the correct
percentage for answers was: 41.4±17.4 for HBV, 33.6
±19.8 for HCV, 70.5±24.1 for HDV, and 36.5±20.7 for
ESLD/HCC. The treatment-related questions were more
challenging: 12.2% correctly answered a HBV treatment
question, 29.6% correctly answered a question about
HCV direct-acting agents and only 15.4% were aware of
anaemia as an adverse event with ribavirin treatment.
However, most (66.5%) indicated that they were com-
fortable with liver disease management. Those who prac-
tised in urban settings were more likely to feel
comfortable with initiating HCV treatment (OR=3.49;
95% CI 1.15 to 10.57). No signiﬁcant predictors for
comfort with HBV treatment were identiﬁed.
Access to screening and treatment and perceived barriers
The main perceived barriers to screening were inability
to pay for diagnostic tests, lack of clinical guidelines and
poor patient awareness. The major HCC screening
barrier was also cost (37.0%) (table 3).
Hepatitis treatment rates were low; 83.3% treated
HCV in <10 patients in the past year and 86.3% treated
HBV in <10 patients/month. Treatment barriers were
multifactorial, with medication cost as the principal
barrier (table 4).
Priorities for screening and management
Physician responses on priorities for hepatitis screening
and treatment aligned with treatment guidelines, with
the majority noting that all high-risk patients should be
screened and treated. However, only 14.8% of physicians
noted that all patients should be treated for HCV and
only 48.4% believed that all patients should be screened
for HBV (tables 5 and 6).
Proposed solutions
Overall, top proposed solutions to improve liver disease
management were universal screening policies (46.4%),
removal of ﬁnancial barriers (27.5%), provider
Table 1 Baseline demographics of the physician
attendees
N (%)
Gender (n=107)
Male 14 (13.1)
Female 93 (86.9)
Age range (n=107) (years)
20–30 11 (10.3)
31–40 29 (27.1)
41–50 44 (41.1)
51–60 19 (17.8)
61–70 4 (3.7)
≥71 0 (0)
Years of practice (n=106)
0–10 30 (28.3)
11–20 30 (28.3)
21–25 19 (17.9)
26–35 23 (21.7)
≥36 4 (3.8)
Specialty (n=106)
Family medicine 0 (0)
Internal medicine 19 (17.9)
Gastroenterology 34 (32.1)
Hepatology 8 (7.6)
Infectious disease 38 (35.9)
Paediatrics 1 (0.9)
Primary medicine practice (n=102)
Referral government hospital 28 (27.5)
General government hospital 53 (52.0)
Referral private hospital 3 (2.9)
General private hospital 12 (11.8)
General primary care public clinic 5 (4.9)
University affiliation (n=100)
Yes—university on campus/trainees involved 29 (29.0)
Yes—university unattached/trainees not
involved
44 (44.0)
Not affiliated 26 (26.0)
Kim YA, Estevez J, Le A, et al. BMJ Open Gastro 2016;3:e000119. doi:10.1136/bmjgast-2016-000119 3
Open Access
group.bmj.com on November 21, 2017 - Published by http://bmjopengastro.bmj.com/Downloaded from 
education (20.3%) and patient education (5.8%).
Physicians rated many provider educational efforts as
helpful, including in-person conferences, web-based
seminars and videoconferences (ﬁgure 1). For disease
screening in particular, these physicians rated local
health fairs and technology-based solutions, such as
mobile applications, highly (ﬁgure 2).
DISCUSSION
This was the ﬁrst published study on Mongolian phys-
ician knowledge of liver disease management and treat-
ment, and the ﬁrst to publish these physicians’
perceptions of barriers and priorities, as well as their
proposed solutions.
Despite their eagerness to screen and treat patients
for liver disease, physicians from all major regions of
Mongolia noted low screening for viral hepatitis (<50%)
and even lower treatment rates (>80% treated <10
patients/year). The main contributing factors were
ﬁnancial and educational in nature. Recommendations
based on physician feedback and information gathered
at the symposium are presented below.
Reimbursement policies for HBV are variable in the
Asia-Paciﬁc region.21 The ﬁnancial barriers are being
addressed by the availability of antiviral medications at
lower costs with a tiered pricing strategy. A ﬁxed-dose
combination of LDV/SOF costs US$400/month in
Mongolia and generic TDF is available at US$25/month
for HBV-infected pregnant women.14 These costs are
expected to decrease further in the near future, as the
manufacturer has signed non-exclusive licensing agree-
ments with seven India-based generic pharmaceutical
manufacturers to expand access to its chronic hepatitis C
medications in developing countries, including
Mongolia.22
Screening test costs still remain a barrier, as the
screening antibody for HCV and HBsAg costs US$3–5
per test, and one hepatitis B DNA or hepatitis C RNA
conﬁrmation test costs US$82–98. Efforts are under way
to increase rates of testing with rapid anti-HCV tests.19
Nonetheless, the main physician-perceived barrier to
screening was patient’s inability to pay for tests; 25.0%,
24.3%, 30.2% and 37.0% of physicians indicated this
barrier for HBV, HCV, HDV and HCC screening,
respectively, since the government currently does not
subsidise these tests.
Recommendations: Ideally, screening, conﬁrmation and
treatment would be universal. However, given the ﬁnan-
cial constraints, access to testing and treatment should
be prioritised according to clinical need, and any prefer-
ential access based on other reasons should not be per-
mitted. According to the provider responses, many
noted that multiple patient subgroups should be priori-
tised for HCV and HBV treatment. For example, 27.2%
of physicians noted that high-risk patients with cirrhosis,
extrahepatic HCV, liver transplant or coexistent liver
disease (eg, dual viral infections or viral infection with
Table 2 Characteristics of physician practices
N (%)
Size of facility (n=102)
≥500 bed hospital 12 (11.8)
300–500 bed hospital 16 (15.7)
100–300 bed hospital 34 (33.3)
≤100 bed hospital 9 (8.8)
2–5 physician clinics 6 (5.9)
≥11 physician clinics 3 (2.9)
Location of practice (n=103)
Rural 40 (38.8)
Urban 63 (61.2)
Patients with liver disease seen per week (n=105)
<10 23 (21.9)
11–30 41 (39.1)
31–50 17 (16.2)
51–75 6 (5.7)
76–100 6 (5.7)
101–150 7 (6.7)
>150 5 (4.8)
Percentage of patients with liver disease with HCV (n=105)
<10 20 (19.1)
11–25 43 (41.0)
26–50 33 (31.4)
51–75 9 (8.6)
76–100 0 (0)
Percentage of patients with liver disease with HBV (n=104)
<10 23 (22.1)
11–25 46 (44.2)
26–50 28 (26.9)
51–75 6 (5.8)
76–100 1 (1.0)
Percentage of patients with liver disease with HDV/HBV
coinfection (n=103)
<10 67 (65.1)
11–25 27 (26.2)
26–50 7 (6.8)
51–75 2 (1.9)
76–100 0 (0)
Percentage of patients with liver disease with
compensated cirrhosis (n=103)
<10 36 (35.0)
11–25 35 (34.0)
26–50 27 (26.2)
51–75 5 (4.9)
76–100 0 (0)
Percentage of patients with liver disease with
decompensated cirrhosis (n=103)
<10 49 (47.6)
11–25 22 (21.4)
26–50 23 (22.3)
51–75 5 (4.9)
76–100 4 (3.9)
Percentage of patients with liver disease with HCC
(n=101)
<10 77 (76.2)
11–25 18 (17.8)
26–50 3 (3.0)
51–75 3 (3.0)
76–100 0 (0)
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; HDV, hepatitis D virus.
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another non-viral liver disease) should be prioritised for
HCV treatment, while 35.8% of physicians did not think
that coexistent liver disease warrants treatment. Given
these varying opinions on who should be treated, clear
prioritisation guidelines should be developed. Forty-six
per cent of physicians also proposed universal screening
efforts as a top priority. These screening efforts can
identify high-risk patients and would also produce the
information necessary to prioritise effectively.
Furthermore, when coupled with properly systematic epi-
demiological surveys, targeted screening efforts can be
used to identify sources and modes of virus transmission
and design prevention interventions to reduce incidence
of new infection. In addition, prioritisation efforts would
beneﬁt from systematic capability to identify, characterise
and monitor patients with liver disease through an inte-
grated national health information system, such as a
patient registry or information module with common
standards, terminology and procedures for data entry.
HCV-TARGET is an example of a registry initiative, an
international consortium of leading HCV investigators
who have developed a common research database with
standardised data parameters and data acquisition pro-
cesses.23 While this database was established to explore
the impact of direct acting antiviral agents, a similar rela-
tively low-cost process, consumed by existing information
systems in Mongolia, can be employed to develop a
patient registry of all patients with viral hepatitis from
diagnosis through treatment to understand the extent of
disease burden and use a data-driven approach to
develop criteria for prioritisation and evaluate
outcomes.23
The educational barriers included poor patient educa-
tion and insufﬁcient provider knowledge of treatment.
To address poor patient education and awareness, physi-
cians indicated that local fairs (rating of 4.2 out of 5), as
well as technology-based solutions (rating of 3.9 out of
5), such as web-based information and mobile educa-
tional applications, would improve screening rates.
Recommendation: Given the high rates of mobile phone
use, mobile educational applications may be an effective
way to disseminate information to larger audiences,
especially since adherence to guidelines is low. For
example, although there are consensus guidelines in the
USA, Europe and Asia for HCC surveillance, the adher-
ence to HCC screening and surveillance is subopti-
mal.24–26 These applications would allow clinical
guidelines to be disseminated directly to the patient with
features such as reminders to encourage better adher-
ence. The patients are then empowered to change the
course of their own disease management. In addition,
any updates can be easily disseminated through the
‘cloud’. In 2014, the four major mobile operators,
MobiCom, Unitel, Skytel and G-Mobile, reported more
than 4.3 million registered users, which indicates that
Mongolian residences own more than one SIM card or
mobile phone.27 Many existing patient education appli-
cations can potentially be translated and available to
patients in Mongolia. In addition, Facebook and social
media platforms can be used to advocate for testing and
treatment. From a cultural and social perspective, the
physicians noted in another question that they did not
see stigma as a barrier to receiving liver disease care in
Mongolia, which is a distinct perspective and suggests
Table 3 Physician perceived barriers of hepatitis and hepatocellular carcinoma screening
Perceived barriers to screening
Hepatitis B
(%)
Hepatitis C
(%)
Hepatitis D
(%)
Hepatocellular
carcinoma (%)
Asymptomatic disease 10.5 18.6 9.4 8.2
Poor patient awareness and education 13.2 21.4 11.5 20.6
Provider’s lack of time and resources 9.2 10.0 2.1 2.7
Lack of screening and management guidelines or awareness of
guidelines
15.8 11.4 24.0 17.8
Patients living too far from laboratories and/or clinics 10.5 4.3 12.5 12.3
Lack of access to hepatitis B treatment 10.5 7.1 5.2 1.4
Patient’s inability to pay for tests 25.0 24.3 30.2 37.0
Difficulty accessing specialty care 5.3 2.9 5.2 0
Table 4 Physician perceived barriers of hepatitis B and C
treatment
Perceived barriers to
treatment
Hepatitis
B (%)
Hepatitis
C (%)
Cost of medication 14.9 25.3
Cost of blood test, medical
visits, in addition to cost of
medication
10.3 8.4
Active substance abuse 1.2 2.1
Active psychiatric comorbidity 0 0
Patient’s fear of side effects 0 0
Lack of consensus about
screening and treatment
guidelines
5.8 10.5
Lack of provider education
about treatment and side
effect management
2.3 0
Distance to treating physicians 0 1.1
More than 3 of above 65.5 52.6
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higher likelihood of an effective social response to
testing and treatment.
Gaps in provider knowledge were conﬁrmed in lower
scores on knowledge-based questions about treatment.
The mean pretest and post-test scores per physician were
60.4±20.4 and 65.6±21.3 with no observed signiﬁcant
predictors for high baseline knowledge or improvement.
This educational symposium was an important step to
prepare physicians to treat and manage hepatitis effect-
ively. Physicians remained engaged during the duration
of the symposium and improved their knowledge
through case studies and lectures. However, future edu-
cational efforts are necessary, and the absence of predic-
tors for knowledge and improvement indicate that
educational efforts need to be applied broadly.
Physicians are eager to learn more, as indicated by the
high ratings for future education efforts. The periodic
in-person conference such as this symposium was the
top preference. The low knowledge of the effect of riba-
virin may reﬂect prior inexperience with interferon-
based treatment.
Recommendations: We advocate broad-based, interactive
case-based medical education tailored to local needs,
based on adequate needs assessment and outcome mea-
surements. Guidelines have also been developed for
HCV diagnosis and treatment, and currently are being
updated for HBV. The high prevalence of HDV and
HCC also warrant an update of these guidelines with a
multidisciplinary team of both international and local
experts forming an advisory panel to draft these guide-
lines. Since HDV is a double viral infection, therapy
requires consideration and targeting of two viral infec-
tions, adding complexity to the management of HDV.11
These efforts are already underway with the launch of
the National Viral Hepatitis Program, which is a
comprehensive programme that involves all aspects
from prevention to care and disease control to meet a
reduction goal for morbidity and mortality due to HBV,
Table 5 Physician survey results on priorities for screening and treatment for CHB
Priorities for screening and management n (%)
Which patients do you think should be screened for hepatitis B infection? (n=64)
High-risk populations (pregnant women, persons with multiple sex partners, inmates, etc) 32 (50.0)
Older patients (>55 years) 1 (1.6)
All patients 31 (48.4)
Which patients with hepatitis B should be prioritised for treatment? (n=74)
All patients with compensated or decompensated cirrhosis, regardless of ALT levels, HBeAg status or HBV DNA
levels
33 (44.6)
Only patients with decompensated cirrhosis, regardless of ALT levels, HBeAg status or HBV DNA levels 12 (16.2)
Adults with CHB who do not have clinical evidence of cirrhosis, but are older and have highly persistently
abnormal ALT levels and evidence of high-level HBV replication, regardless of HBeAg status
24 (32.4)
Patients with persistently abnormal ALT levels alone, regardless of HBeAg status (where HBV DNA testing is
not available)
5 (6.8)
Which patients need to be screened for HDV coinfection? (n=86)
Patients known to be HBsAg positive and symptomatic 37 (43.0)
All patients known to be HBsAg positive, including asymptomatic patients 40 (46.5)
Patients with acute hepatitis B who are not yet HBsAg positive, but are IgM anti-HBc positive 4 (4.7)
Chronic HBV carriers with a history of or active injection drug use 4 (4.7)
No patients should be screened 1 (1.2)
ALT, alanine aminotransferase; anti-HBc, hepatitis B core antibody; CHB, chronic hepatitis B; HBeAg, hepatitis B envelope antigen;
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HDV, hepatitis D virus.
Table 6 Physician survey results on priorities for
screening and treatment for chronic hepatitis C
Priorities for screening and management n (%)
Which patients need to be screened for HCV infection?
(n=91)
A. History of or current injection drug use 3 (3.3)
B. Healthcare workers 1 (1.1)
C. Children born to HCV-infected women 0 (0)
D. Prior recipients of medical procedures, such
as transfusions, organ transplants,
haemodialysis, surgical procedures
4 (4.4)
E. Patients with unexplained ALT levels 2 (2.2)
F. All patients with A–E 65 (71.4)
G. All older patients 16 (17.6)
Which patients should be prioritised for HCV treatment?
(n=81)
A. Patients with advanced fibrosis or cirrhosis
(stages 3–4)
11 (13.6)
B. Patients with cirrhosis 1 (1.2)
C. Liver transplant recipients or patients on
immunosuppression for other diseases
1 (1.2)
D. Patients with severe extrahepatic hepatitis C 3 (3.7)
E. Patients with HIV coinfection 2 (2.5)
F. Patients with HBV coinfection 0 (0)
G. Patients with other coexistent liver diseases
(eg, NASH)
29 (35.8)
H. All patients A–G 22 (27.2)
I. All patients with chronic HCV regardless of
severity
12 (14.8)
ALT, alanine aminotransferase; HBV, hepatitis B virus;
HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis.
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HDV and HCV. The MOHS also provides strong
support on HBV and HDV clinical guideline develop-
ment and HCV guideline updates.28 Other existing
regional guidelines for HBV reﬂect signiﬁcant regional
variation, and new guidelines relevant to the needs of
Mongolian patients are essential since application to
Mongolia depends on resource infrastructure and differ-
ences in local epidemiology.29–34 Education of providers
can be addressed by remote educational programmes
such as Project ECHO (Extension for Community
Healthcare Outcomes), which can provide access to spe-
cialty care and consultation for patients and physicians
in smaller cities as well as international hepatologists to
serve as mentors and colleagues for hepatologists in
Mongolia. Training also includes case-based learning,
didactic presentations, case consultations and videocon-
ferences. One study found that the quality of hepatitis
C care provided by ECHO-trained primary care provi-
ders was equivalent to care provided by university-based
specialists.35 Lessons from HIV management in other
developing countries also suggest the need to dissemin-
ate knowledge to other providers besides physicians,
such as community health workers, to lessen the
burden on providers and expand access to care to all
patients. Project ECHO can be used to train other types
of providers as well.36–38
Figure 2 Mean ratings for proposal of future efforts to improve screening (1 as ‘least useful’ to 5 as ‘most useful’).
Figure 1 Mean ratings for proposal of future educational programmes to improve provider knowledge (1 as ‘least useful’ to 5 as
‘most useful’). CME, Continuing Medical Education.
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Finally, this type of provider needs assessment of both
knowledge and their perceptions is necessary to under-
stand the educational efforts that would resonate with
providers in the local community. Local and country-
speciﬁc disease knowledge is important, because there
may be unique disease determinants or distribution. In
Mongolia, the prevalence of HBV/HDV coinfection is
very high (over 10% compared with <5% in most other
endemic areas in the world) and is known to associate
with more rapid disease progression.10–12 Among
HCV-infected persons, almost all (98%) have genotype
1b and two-third demonstrated Q80k polymorphism,
both of which can have implication in regard to
response to antiviral therapy.39 40 Overall, there is much
heterogeneity for HCV among Asians depending on
local epidemiology and even coinfection dominance of
HCV/HBV differs by ethnicity, which may also contrib-
ute to potential differences in disease progression and
treatment response.41 42 Furthermore, there are known
differences in survival for patients with HCC depending
on ethnic heterogeneity, reiterating the importance of
understanding local patterns of disease.43–46 Regarding
physician perception, this can be inﬂuenced by the
obvious cultural and patient population differences
which are usually addressed and considered, but the
inﬂuence by provider variations is also very important
but often overlooked. Mongolia is an example of a
unique physician demographic with 86.9% female,
38.8% practising in rural areas and having limited
experience with managing antiviral treatment. In con-
trast, a neighbouring country, China, has 55.3% male
physicians.47 Mongolia’s educational needs will most
likely be very different from those of other developing
countries and will evolve over time as exposure to treat-
ment management increases. As such, this type of needs
assessment should be periodically conducted to meet
the evolving educational needs.
Limitations of this study include the subjective nature
of the surveys, which may lead to overestimates in prac-
tice pattern questions, although the survey methodology
allowed for perceptions to be accurately captured.
Another limitation is that all of the attendees were physi-
cians and other types of providers were not present.
Most physicians were also specialists and university
afﬁliated. However, the physicians come from all major
provinces and represent a diverse geographic sample
out of a total of ∼8500 physicians of all specialties
serving a population of close to 3 million people.3 The
ﬁrst step should be to educate specialists and physicians,
but expansion and task shifting to other providers is
necessary for more efﬁcient and broader access to care.
Nevertheless, the study surveyed physicians from diverse
geographic regions of Mongolia and the survey also had
a high response rate with 74.1% of questions responded
to by at least 50–75% of participants.
In conclusion, physicians from all major regions of
Mongolia highlighted the need to remove ﬁnancial bar-
riers to screening for viral hepatitis and increase access
to safe and effective treatment through well-designed
and targeted patient and provider educational efforts.
Our observations reveal that there are abundant oppor-
tunities in Mongolia to strengthen health service deliv-
ery for people living with viral hepatitis and liver disease.
There is a youthful, energetic, motivated medical com-
munity and government who are committed to expand-
ing capacity for clinical services. The survey has exposed
requirements needed for a successful scale-up of these
services such as removal of ﬁnancial constraints to
testing and treatment, and advancing patient and pro-
vider education, which can be achievable using more
innovative digital health approaches. Innovative
approaches to broad-based screening, low-cost diagnos-
tics and medical education, advocacy and patient out-
reach, especially using some newer forms of digital
technologies, can be expected to have a signiﬁcant
impact on the public health of Mongolia. Beyond
Mongolia, this work outlines a process and provider
survey methodology that can be applied to other
developing countries in order to understand local needs
and develop targeted recommendations for educational
and organisational approaches to expand care.
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